KUALA LUMPUR: Apart from non-pharmaceutical interventions (lockdowns or other restrictions) and vaccination, prophylaxis (treatment given or action taken to prevent disease or its severity) is another pathway to flatten the curve that to date has been given less attention than it deserves.
Vitamin D (VitD), as one of the central elements of our immune system, inexpensive and relatively safe side-effect profile molecule toxic only in extremely high doses, has captivated scientists’ interest as one potential prophylactic since the onset of the COVID-19 pandemic.
The science behind VitD’s crucial immuno-modulating role is long-established (excellent reviews here: 1, 2, 3). Figure 1 summarises some technicalities important to this discussion.
The figure above shows VitD synthesis in our body from its inactive form (D2/D3) to active form through the process of subsequent hydroxylation in our liver and kidney.
The VitD helps our innate immune cells to produce beta-defensins and cathelicidins. These peptide nano-soldiers keep the first line of defence (see Figure 1) immediately as a virus enters the body and until the adaptive immune response is activated (which happens in about 7-10 days for the first infection or within 1-2 days in case of reinfection). In other words, even before our B-cells start producing antibodies, beta-defensins and cathelicidins, which can be produced in the right quantity only in VitD sufficiency, can significantly inhibit viral entry into the cells and its replication.
Furthermore, a sufficient level of active VitD inhibits the production of proinflammatory cytokines (IL-2, IL-12, INF-Gamma, IL-6, IL-8, IL-17) while upregulating anti-inflammatory cytokines (IL-4, IL-5, IL-10) (see Figure 1 for more insights). In other words, VitD down-regulates our immune system response towards the humoral pathway (antibody production), which is less inflammatory and therefore reduces the possibility of the cytokine storm.
VitD has other functions essential in fighting SARS-CoV-2 such as reinforcing physical barrier function in epithelial, intestinal, lung and corneal cells, inducing autophagy of the infected cells, which leads to reduced replication of virus—mechanism found to be suppressed by SARS-CoV-2 (VitD here works similar to ivermectin less its side effects), increasing surfactants that prevent alveolar collapse and many more.
Malaysia health authorities have been looking into the VitD and SARS-CoV-2 association at the pandemic onset (1, 2). However, no action was taken due to a lack of sufficient evidence at that time.
Nevertheless, to date, empirical evidence on the close association between SARS-CoV-2 and VitD multiplied many folds. To get a quick but robust overview of the empirical evidence, it is helpful to look at the most recent systematic meta-analytical studies, which are statistical studies on the large number of empirical studies pooled together (summary statistics in Figure 2).
The above systematic reviews of numerous studies (Figure 2.A) now convincingly suggest that VitD deficiency defined as 25-OH D < 20 ng/mL is significantly associated with the risk of Covid-19 infection, the severity of its outcomes and mortality.
Although, like some authors rightfully pointed out, association does not imply causation, several clinical trials on VitD supplementation as a therapeutic intervention in SARS-CoV-2 management shed some light on the causal direction.
Two most recent meta-analytic studies (Figure 2.B) looked into the existing observational, cross-sectional and even randomised clinical trials for VitD supplementation to SARS-CoV-2 patients and reported the following. The odds of Intensive Care Unit (ICU) admission, need for mechanical ventilation, and mortality were significantly lower in the VitD intervention group than in the placebo group. In all meta-analysed studies, there was inclusion of hypertension, diabetes and corticosteroid use patients. No side effects or adverse events related to VitD intervention is reported.
The above meta-analytic studies did not include another more recent published clinical trial due to the timing of publication. This randomised clinical trial (although single centre) found that therapeutic improvement in serum VitD levels to 80–100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 with no side-effects. Among the participants, hypertension and diabetes patients were present as well.
The discussion of modes and doses used in any of the above-mentioned clinical trials is intentionally left outside of this article. They are the purview of healthcare specialists and should not be motivation to self-treatment by the general public.
Overall, the convincing empirical results congruent with the well-established theory on VitD are there, but let’s take correct conclusions and corrective measures.
First of all, VitD sufficiency is not a silver bullet against SARS-CoV-2 severity, unlike vaccines. However, VitD deficiency should be recognised at least as a valid and important risk factor for SARS-CoV-2 infection and its severity.
Second, given the accumulated empirical evidence, VitD supplementation intervention in deficiency cases now sounds like a compelling additional strategy to flatten the curve. It is important to note that many studies indicated importance of early VitD intervention, at least immediately upon admission to the hospital as starting supplementation upon ICU admission could be too late.
Therefore, healthcare authorities could consider making serum VitD deficiency screening standard operating procedure upon positive polymerase chain reaction test. Early VitD supplementation (in the form of oral vitamin D3 or calcifediol) can be considered for cases with VitD deficiency (25-OH D < 20 ng/mL) and even its insufficiency (25-OH D < 30 ng/mL)— generally accepted thresholds in the medical literature. This proactive strategy may result in lower hospital admission and subsequent progression of severity while reliving our overwhelmed healthcare system.
Third, this is not in any measure a call for self-treatment! VitD can be toxic in extremely large doses or even in only relatively large doses taken for a prolonged period. Furthermore, unsupervised VitD intake can be risky for people with cardiovascular issues, hypertension, and some other underlying health conditions because VitD primary function in our body is to maintain calcium and phosphate levels. Therefore, unsupervised VitD intake may lead to calcification and other complications. VitD supplementation would also require intake of other essential minerals such as calcium, magnesium, vitamin K2 and others. Therefore, qualified medical assessment, advice and supervision on the mode of intake, correct dosage and duration is the absolute requirement.
Last but not least is the long-term takeaway. The airborne nature of SARS-CoV-2 has taught us that ignoring the state and standards of our ventilation and filtration systems nationwide is a ticking bomb. Now this virus is drawing our attention to the long-standing problem of VitD deficiency prevalence on the national scale, which to date seems to be not given the proper attention and intervention. The fact that pandemic management has pushed more families to the poverty line should ring even louder alarm as VitD deficiency is well known to be prevalent in low-income individuals.
SARS-CoV-2 made our lives miserable in many ways. However, would we be able to appreciate the valuable lessons it taught us? Remember that crisis management theory 99% time talks about the value of being proactive!
Rais Hussin and Margarita Peredaryenko are part of the research team at EMIR Research, an independent think tank focused on strategic policy recommendations based on rigorous research.
** The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the position of Astro AWANI.
Dr Rais Hussin, Dr Margarita Peredaryenko
Thu Jul 22 2021
VitD deficiency should be recognised at least as a valid and important risk factor for SARS-CoV-2 infection and its severity. - ETX Studio
KKM kekal keputusan pinda Akta Perubatan 1971
KKM kekal dengan keputusan untuk meminda Akta 50 bagi menangani jurang antara PPP dan Program Sarjana Perubatan tempatan biarpun mendapat bantahan sesetengah pihak.
Malaysia-China bincang perkukuh kerjasama sektor pendidikan tinggi
Sempena sambutan Ulang Tahun ke-50 Hubungan Diplomatik, Malaysia dan China bincang inisiatif strategik perluas dan perkukuh jalinan kerjasama sektor pendidikan tinggi.
Freedom Flotilla to Gaza: Semua delegasi diminta pulang, FFC akan maklumkan tarikh baharu misi
Freedom Flotilla Coalition tidak dapat meneruskan misi penghantaran bantuan ke Gaza untuk kali ini.
Biden rancang untuk berdebat dengan Trump
Sebelum ini, Biden tidak komited untuk berdebat dengan lawannya, Trump.
Pesta Kaamatan 2024 dilancar pada 1 Mei di Ranau, Sabah
Sambutan perayaan Pesta Kaamatan 2024 akan dilancarkan pada 1 Mei di Ranau dan diadakan sambutan di peringkat daerah, di Sarawak dan Semenanjung.
Khairulnizam layak ke Sukan Olimpik Paris 2024
Khairulnizam Mohd Afendy sah akan mengiringi Nur Shazrin Mohd Latif ke Sukan Olimpik Paris 2024, juga merupakan penampilan keempat berturut-turut di temasya berprestij itu.
Musibah banjir buka peluang 'rezeki lebih' usahawan F&B melalui IPR
Musibah banjir yang melanda Johor tahun lepas membuka peluang rezeki baharu kepada usahawan makanan dan minuman, Haida Abdul Rahman.
Mohd Azizulhasni tekad dikalungkan pingat emas di Paris
Azizulhasni tekad untuk 'dikalungkan' pingat emas pertama Malaysia di Sukan Olimpik Paris 2024 pada penampilan terakhirnya di temasya itu.
USM cipta rekod hasilkan kaligrafi Cina 2.68km
Penuntut USM cipta rekod dalam MBOR apabila menghasilkan penulisan kaligrafi Cina sepanjang 2.68 kilometer.
MITRA sudah belanja RM40 juta daripada peruntukan RM100 juta tahun ini
Sebanyak RM40 juta daripada peruntukan RM100 juta yang disalurkan kerajaan tahun ini kepada MITRA telah dimanfaatkan untuk pelbagai program.
Pakar dakwa nitrik oksida, vitamin D mampu rawat COVID-19
Nitrik oksida yang disedut dikenal pasti dapat menyelamatkan banyak bayi baru lahir yang kekurangan oksigen dengan kecacatan jantung.